GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2006

Separate Manufacturing Deals Inked at Cleveland BioLabs and Viron Therapeutics

  • Cleveland BioLabs (CBLI) and SynCo Bio Partners completed the transfer of technology in their joint effort to produce CBLI's lead product, Protectan CBLB502, and have signed an agreement to produce sufficient amounts for clinical trials and the commercial market.

    SynCo will work with CBLI to develop the manufacturing process, as well as manufacture CBLB502 for Phase I trials and commercial release.

    Viron Therapeutics signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing of VT-111. Under the agreement, Diosynth Biotechnology will support the process improvement, process development, and clinical product manufacturing.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »